The U.S. negotiates Medicare drug price cuts that will save billions for U.S. citizens

Story: 2024 C.E.  |  Last updated: May 1, 2026

For the first time in its six-decade history, Medicare gained the legal power to negotiate prescription drug prices directly with pharmaceutical companies — and the results of that first round could save Americans an estimated $6 billion annually once the new prices take effect in 2026 C.E.

At a glance

• Medicare drug price negotiation: The U.S. government announced negotiated prices for 10 widely used drugs in August 2024 C.E., marking the first time Medicare was legally permitted to bargain directly with drugmakers.
• Prescription cost savings: The negotiated prices represent discounts of up to 79% off list price, with the steepest cuts applied to drugs that had faced the least market competition.
• Inflation Reduction Act: The 2022 C.E. law that made negotiations possible also caps out-of-pocket drug costs for Medicare enrollees at $2,000 per year beginning in 2025 C.E.

What changed — and why it took so long

Medicare, the federal health program covering roughly 67 million older and disabled Americans, was created in 1965 C.E. For nearly 60 years, lawmakers explicitly barred it from negotiating drug prices — a restriction that made the U.S. an outlier among wealthy nations, most of which negotiate drug costs as a matter of course.

That changed when Congress passed the Inflation Reduction Act in 2022 C.E. The law gave the Department of Health and Human Services authority to negotiate prices for a limited number of high-cost drugs each year. The first 10 drugs on the list were selected based on their cost to Medicare and the lack of generic or biosimilar competition — meaning patients had no cheaper alternative to turn to.

The drugs selected in that first round include treatments for blood clots, diabetes, heart failure, and autoimmune conditions. Eliquis, the blood thinner that ranks among Medicare’s highest expenditures, was among them. So was Januvia, a common diabetes medication. Together, the 10 drugs accounted for roughly $50 billion in Medicare spending in 2022 C.E. alone.

The numbers behind the savings

The Biden administration projected $6 billion in annual savings once the negotiated prices go live in January 2026 C.E. Over a decade, the Centers for Medicare and Medicaid Services estimated the program could reduce federal drug spending by $100 billion or more, depending on how many drugs are added to future negotiation rounds.

For individual patients, the savings are tangible. Some enrollees previously paying thousands of dollars a year for certain drugs will see their costs drop significantly. The $2,000 annual out-of-pocket cap that took effect in 2025 C.E. compounds this effect, particularly for people managing chronic conditions that require multiple medications.

The negotiated discounts range widely. Some drugs received modest reductions; others were cut by more than 75%. The variation reflects the complexity of each negotiation and the degree to which a drug dominates its therapeutic category without competition.

What the pharmaceutical industry argued — and what the courts decided

Drugmakers did not accept the new framework quietly. Several major pharmaceutical companies filed lawsuits arguing that compelled negotiation amounted to unconstitutional coercion — that accepting government-set prices under threat of steep excise taxes was not a genuine choice. Federal courts dismissed multiple challenges, finding that manufacturers retained the option to withdraw their drugs from Medicare and Medicaid — an option none ultimately exercised.

The legal battles revealed the underlying tension in any system where a single large buyer sets prices. Pharmaceutical companies argue that lower prices reduce the revenue needed to fund research into future treatments. Independent analyses of this claim are mixed. Some economists find modest negative effects on R&D investment at the margins; others find the relationship weak. Research published in Health Affairs suggests that price negotiation programs in other countries have not systematically suppressed pharmaceutical innovation over time — though the debate remains genuinely unresolved.

A milestone with real limits

The program is significant, but its scope is narrow by design. In its first year, it covers 10 drugs. The law allows for 15 more in the second round, 15 in the third, and 20 in each subsequent year. Even at full scale, negotiation will touch only a fraction of the drugs Medicare covers. Generic drugs and drugs with existing biosimilar competition are excluded entirely.

Critics from the left argue the program doesn’t go far enough, pointing to countries like Canada, Germany, and Australia where governments negotiate prices across entire drug categories. Critics from the right contend the program sets a precedent that will chill private investment. Both criticisms reflect real trade-offs that the policy does not fully resolve.

What’s undeniable is the precedent itself. The Kaiser Family Foundation noted that the mere act of establishing negotiation — after decades of legal prohibition — shifts the structural relationship between the U.S. government and the pharmaceutical industry. Whether future administrations expand or roll back the program, the ceiling on what was once considered politically impossible has moved.

For the roughly 9 million Medicare enrollees who use the 10 negotiated drugs, the impact in 2026 C.E. will be direct and measurable. For the broader question of how a wealthy democracy balances drug access with pharmaceutical innovation, the answer remains genuinely open.

Read more

For more on this story, see: Reuters

For more from Good News for Humankind, see:

• Alzheimer’s risk cut in half by drug in landmark prevention trial
• Marie-Louise Eta becomes the first female head coach in men’s top-flight European football
• The Good News for Humankind archive on global health

About this article

• 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
• 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
• 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
• ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.